Index

Note: Page numbers followed by f and t indicate figure and table, respectively.

Abdominal cavity procedures
  intraperitoneal catheters, 62–63
  paracentesis, 61–62
Abdominal hysterectomy, 173–174
Abdominopelvic radiotherapy, 474
Abscess, tubo-ovarian, 249
ACCP. See American College of Chest Physicians (ACCP)
Acetaminophen, 455
  and NSAIDs (Algorithm), 465
Acid–base derangements, 82–87
  metabolic component of, 85
  respiratory and metabolic components of,
  t
  summary of, 84t
Acid–base homeostasis, 76–87
  acid-base derangements, 82–87
  bicarbonate/carbon dioxide buffer system,
  t
  buffer system for, 78–79
  edema, causes of, 78t
  exchange of water, 77t
  tubular acid secretion, rate of, 80
ACP Journal Club, 18
ACTH. See Adrenocorticotropic hormone (ACTH)
Acute myocardial ischemia, 134–135
Acute pain, 448–449
Acute renal failure, 211
Acute respiratory distress syndrome (ARDS), 380
Acute tubular necrosis, 211
Adaptojen, 494
Adenocarcinoma in situ (AIS), 476
ADH. See Antidiuretic hormone (ADH)
Adjuvant analgesic drugs, 460–461
  for cancer pain (Algorithm), 467
Adjuvant therapy, 349f. See also under
  Endometrial cancer
  Adjuvant therapy for ovarian cancer
  intraperitoneal therapy, 370
  intravenous chemotherapy, 369–370
  maintenance therapy, 370–371
  postoperative chemotherapy, 371
  asymptomatic recurrence, 373
  evidence, absence of, 372–373
  persistence, 371–372
  symptomatic recurrence, 373–374
Adrenal insufficiency prophylaxis, 187–188
Adrenocorticotropic hormone (ACTH), 163
Agency for Healthcare Research and
  Quality, U.S. (AHRQ), 526
Aging population, optimal care of, 7
AHA. See American Heart Association (AHA)
AHRQ. See Agency for Healthcare Research
  and Quality, U.S.
Air embolism, 47–48
Albumin, 93
  postoperative, 162
Aldosterone, 164
Alimentary tract, access to, 117–118
Allen stirrups, 282
Alternate gases
  argon, 263
  nitrous oxide, 263
American Association of Gynecologic
  Laparoscopists (AAGL), 267
American College of Cardiology, 150
Index

American College of Chest Physicians (ACCP), 186
American Heart Association (AHA), 150, 177
American Society of Anesthesiology (ASA), 150, 237
American Society of Clinical Oncology (ASCO), 186
Aminoglycoside, 209
Ampicillin, 197
Analgesia
  patient-controlled opiate, 457–458, 457f
  preemptive 450
Analgesics, 194
  ladder, 453
Anemia, 380–381
Anesthesia, 379
  complications with, 272–273
  epidural, 285
  inhalational, 267
Angiotensin, 80
Anion gap, 85
Anorexia, 517
ANP. See Atrial natriuretic peptide (ANP)
Antacids, 187
Antibiotic prophylaxis, 176–179
  endocarditis prophylaxis, 177
  intensive-care patients and special considerations, 177–179
Anticonvulsants, 460
Antidepressants, 460
Antidiuretic hormone (ADH), 71, 267
Antimicrobial prophylaxis, 242–244
Anxiety, 435–436
Arginine, 497
Argon, 263
Argon beam coagulator (ABC), 263
ARTEMIS trial, 185
Arterial occlusion, 401–402
ASA. See American Society of Anesthesiologists (ASA)
Ascites, 522–523
  management of, 107–108
ASCO. See American Society of Clinical Oncology (ASCO)
Aspirin therapy, 207
Atelectasis, 209
Atrial natriuretic peptide (ANP), 72

Average total cost, 33
Aztreonam, 176
β-hemolytic streptococcal septicemia, 207
Bacteremia, catheter-related, 246
Bacterial translocation, 178
Bacterial vaginosis, 242
Bacteroides fragilis, 236
Balloon deflation, at pulmonary artery, 55
Baratrauma, 400
Barrier devices, use of, 240
Basal metabolic requirements (BMR), 193
Base deficit, 85
Base excess, 85
Basset procedure, 390
Beck depression inventory, 423
Behavioral pain scale, 511
Bell Telephone Laboratories, 12
Benzodiazepines, 520, 525
Best evidence, 20
Best practices loop model, for EBM, 36
  evidence-based continuous feedback, 36f
Bicarbonate
  carbon dioxide buffer system, 77
  reabsorption, in proximal tubules, 81
  therapy, 106
Biochemistry/electrolyte tests, 149
Bisphosphonate therapy, 519
Bladder drainage, 309
Bladder dysfunction, postoperative, 312–313
Bladder injury, 280–281
Bleeding, 528, 529t
  control measures in cancer patient, 529t
  perioperative, 202–203
Bleomycin sclerotherapy, 403
Blood component therapy, 202–203
Blood urea nitrogen (BUN), 146
BMR. See Basal metabolic requirements (BMR)
Body fluid compartments, 70t
Body mass index (BMI), 275
Bowel preparation
  for intestinal surgery, 174–176
  in laparoscopy, 279f
  mechanical, 240–241
  preoperative 308
Brachial palsy, 282
Brachytherapy, 347
Breast cancer, 444
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bricker procedure</td>
<td>321</td>
</tr>
<tr>
<td>British Medical Journal</td>
<td>23</td>
</tr>
<tr>
<td>Broviac catheter</td>
<td>53</td>
</tr>
<tr>
<td>Buffers</td>
<td>77</td>
</tr>
<tr>
<td>BUN. See Blood urea nitrogen (BUN)</td>
<td></td>
</tr>
<tr>
<td>Calorie requirement</td>
<td>111, 111t, 112t</td>
</tr>
<tr>
<td>CAM. See Complementary and alternative medicine (CAM)</td>
<td></td>
</tr>
<tr>
<td>Camper's fascia, closure of</td>
<td>244</td>
</tr>
<tr>
<td>Cancer cachexia syndrome</td>
<td>137</td>
</tr>
<tr>
<td>Cancer pain syndromes</td>
<td>450–452</td>
</tr>
<tr>
<td>Cancer patients, nutritional support in,</td>
<td>136–138</td>
</tr>
<tr>
<td>Candida albicans</td>
<td>252</td>
</tr>
<tr>
<td>Candidemia</td>
<td>246</td>
</tr>
<tr>
<td>Carbapenems</td>
<td>249</td>
</tr>
<tr>
<td>Carbon dioxide</td>
<td>262–263</td>
</tr>
<tr>
<td>Cardiac arrhythmia</td>
<td>47, 271</td>
</tr>
<tr>
<td>Cardiac assessment, perioperative</td>
<td>170–171, 170t</td>
</tr>
<tr>
<td>Cardiac insufficiency</td>
<td>208</td>
</tr>
<tr>
<td>Cardiac output (CO)</td>
<td>163</td>
</tr>
<tr>
<td>Cardiorespiratory insufficiency</td>
<td>377–379</td>
</tr>
<tr>
<td>Cardiovascular collapse. See under</td>
<td></td>
</tr>
<tr>
<td>Laparoscopy</td>
<td></td>
</tr>
<tr>
<td>Case–control studies</td>
<td>21–22</td>
</tr>
<tr>
<td>Catheter</td>
<td></td>
</tr>
<tr>
<td>complications related to</td>
<td>48</td>
</tr>
<tr>
<td>infection</td>
<td>48–50</td>
</tr>
<tr>
<td>comprehensive analysis of</td>
<td>49</td>
</tr>
<tr>
<td>definition of</td>
<td>246</td>
</tr>
<tr>
<td>knotting</td>
<td>56</td>
</tr>
<tr>
<td>thrombosis related to</td>
<td>50–51</td>
</tr>
<tr>
<td>CBC. See Complete blood count (CBC)</td>
<td></td>
</tr>
<tr>
<td>CEBM. See Centre for Evidence Based Medicine (CEBM)</td>
<td></td>
</tr>
<tr>
<td>Cefotaxime</td>
<td>176</td>
</tr>
<tr>
<td>Cefoxitin</td>
<td>176, 249</td>
</tr>
<tr>
<td>Ceftaxime</td>
<td>176</td>
</tr>
<tr>
<td>Ceftriaxone</td>
<td>249</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>394–395</td>
</tr>
<tr>
<td>Central vein, inability to identify</td>
<td>46–47</td>
</tr>
<tr>
<td>Central venous catheters</td>
<td>245–246</td>
</tr>
<tr>
<td>Central venous line blockage, management of, 52t</td>
<td></td>
</tr>
<tr>
<td>Central venous pressure (CVP)</td>
<td>380</td>
</tr>
<tr>
<td>Centre for Evidence Based Medicine (CEBM)</td>
<td>19</td>
</tr>
<tr>
<td>Cephalosporins</td>
<td>209, 243, 252</td>
</tr>
<tr>
<td>Cervical carcinoma</td>
<td>299, 444, 475–478</td>
</tr>
<tr>
<td>and coexisting pregnancy</td>
<td>319–321</td>
</tr>
<tr>
<td>for early stage</td>
<td></td>
</tr>
<tr>
<td>fertility-preserving surgery</td>
<td>318–319</td>
</tr>
<tr>
<td>laparoscopic lymph node staging</td>
<td>317</td>
</tr>
<tr>
<td>radical vaginal hysterectomy</td>
<td>317–318</td>
</tr>
<tr>
<td>robotic radical hysterectomy</td>
<td>318</td>
</tr>
<tr>
<td>sentinel node identification</td>
<td>317</td>
</tr>
<tr>
<td>total laparoscopic radical hysterectomy</td>
<td>318</td>
</tr>
<tr>
<td>mortality, operative</td>
<td>304t</td>
</tr>
<tr>
<td>postoperative assessment and management</td>
<td></td>
</tr>
<tr>
<td>activity</td>
<td>310</td>
</tr>
<tr>
<td>diet and nutrition</td>
<td>311</td>
</tr>
<tr>
<td>follow-up</td>
<td>312</td>
</tr>
<tr>
<td>intake and output</td>
<td>311</td>
</tr>
<tr>
<td>laboratory tests</td>
<td>310</td>
</tr>
<tr>
<td>pulmonary care</td>
<td>311</td>
</tr>
<tr>
<td>wound care</td>
<td>311–312</td>
</tr>
<tr>
<td>radical hysterectomy</td>
<td></td>
</tr>
<tr>
<td>extended</td>
<td>305</td>
</tr>
<tr>
<td>extrafascial</td>
<td>305</td>
</tr>
<tr>
<td>intraoperative considerations</td>
<td>308–310</td>
</tr>
<tr>
<td>modified</td>
<td>305</td>
</tr>
<tr>
<td>partial exenteration</td>
<td>305</td>
</tr>
<tr>
<td>preoperative evaluation</td>
<td>306–307</td>
</tr>
<tr>
<td>preoperative preparation</td>
<td>307–308</td>
</tr>
<tr>
<td>surgical complications</td>
<td></td>
</tr>
<tr>
<td>lymphedema and lymphocysts</td>
<td>316–317</td>
</tr>
<tr>
<td>postoperative bladder dysfunction</td>
<td>312–313</td>
</tr>
<tr>
<td>pulmonary embolism</td>
<td>317</td>
</tr>
<tr>
<td>sexual function after radical hystectomy</td>
<td>313–314</td>
</tr>
<tr>
<td>ureteral injuries in pelvic surgery</td>
<td>315t</td>
</tr>
<tr>
<td>surgical treatment of</td>
<td></td>
</tr>
<tr>
<td>advanced and recurrent</td>
<td>303–304</td>
</tr>
<tr>
<td>microinvasive adenocarcinoma</td>
<td>301</td>
</tr>
<tr>
<td>microinvasive cervix cancer</td>
<td>300–301</td>
</tr>
<tr>
<td>stage IB1</td>
<td>301–302</td>
</tr>
<tr>
<td>stage IIB and greater</td>
<td>302–303</td>
</tr>
<tr>
<td>ureteral obstruction</td>
<td>321–322</td>
</tr>
<tr>
<td>Chemoreceptor trigger zone (CTZ)</td>
<td>194</td>
</tr>
<tr>
<td>endometrioid</td>
<td>347–349</td>
</tr>
<tr>
<td>intravenous</td>
<td>369–370</td>
</tr>
</tbody>
</table>
542  Index

Chemotherapy (Continued)
  ovarian function preservation during, 471–473
  postoperative. See under Adjuvant therapy
  for ovarian cancer
  UPSC (uterine papillary serous
carcinoma), 349–350, 349t
Chest radiograph, 151–154, 306
  abnormality by age, 153t
  risk factors for, 153t
Chest tube thoracostomy, 47, 58–60, 268
  complications of, 59–60
  overview, 58–59
  procedure for, 59
Chest X-ray, 335. See also Chest radiograph
CHF. See Congestive heart failure (CHF)
Chitosan, 498
Chlorhexidine, 241
Chronic obstructive pulmonary disease
  (COPD), 210
Chronic pain, 449
Chronic renal failure, 212
CI. See Confidence intervals (CI)
Cigarette smoking, 398
Cirrhosis, 213
Cleansing, preoperative, 240
Clindamycin, 176
Clonidine, 460
Clostridium difficile colitis, 252
Clostridium difficile, 178
CO. See Cardiac output (CO)
Coagulation studies, 147–148, 381
  Cochrane collaboration, 18
Cohort studies, 22
Colitis, pseudomembranous
  antibiotic-induced, 251
Collagen synthesis, 396, 397
Colloid infusions, 92
Colloid osmotic pressure, 75, 76f, 162
Colloid preparations, 91t
Colonic stents, 516
Colostomy, 280
Comfortex DeCube, 199
Complementary and alternative medicine
  (CAM), 488–490
Complete blood count (CBC), 145, 148
  Complete compatibility testing, 148–149
  Confidence intervals (CI), 24
  Congestive heart failure (CHF), 165
Consensus conferences, 23
Consolidated Standards of Reporting Trials
  (CONSORT), 13
CONSORT. See Consolidated Standards of
  Reporting Trials (CONSORT)
Constipation, 521–522
Cookbook medicine, 6
COPD. See Chronic obstructive pulmonary
disease (COPD)
Core zone receptors, 165
Corticosteroids, 460
Cost(s), 25f
  Cost–benefit analysis, 34
  Cost minimization analysis, 32
  Cost-to-charge ratios, 32
  Cost utility analysis, 33
Coumadin, 56
Cowden’s syndrome, 331
Cr. See Creatinine (Cr)
Creatine (Cr), 146
Critical care economics, 7–8
CTZ. See Chemoreceptor trigger zone (CTZ)
Cycloallin, 493
Cystitis, 250
Cystocele, 404
Cystoscopy, 314
Dacron cuff, 53, 63
Databases, for EBM, 17
Death
  and dying, issues of. See under
    Psychosocial considerations,
    perioperative
  neonate, 431t
Decision analysis primer, 29–31
Decubital care, 198–200
Decubitius ulcers, 198
Deep incisional SSI. See under Superficial
  and deep incisional SSI
Deep vein thrombosis (DVT), 51, 181
  risk factors for, 180t, 181f
Deep venous thrombosis, 273–274, 274t, 401
Deep venous thrombosis prophylaxis,
  336–337, 336t
Depression, 436
  postsurgical, treatment of, 436–437
Deming, W. E, 4, 11
Dextrose, 100
Diabetes, 205–207
  management of, 239–240
Diagnostically related groups (DRG), 32
Diagnostic imaging, 335
Diet and nutrition, 311
Dietary Supplement Health and Education Act (DSHEA), 487
Dietary supplements, perioperative. See Herbal medication, perioperative
Docosahexaenoic acid (DHA), 498
Drains, 245
Delirium, 433–434
ICU, treatment and prevention of, 434–435
DRG. See Diagnostically related groups (DRG)
Drug abuse/addiction, 445
Drug toxicity, 125–126
Duodenal feedings, 117
DuoDerm, 200
Duplex ultrasound, 51
DVT. See Deep vein thrombosis (DVT)

EBM. See Evidence-based medicine (EBM)
ECF. See Extracellular fluid (ECF)
ECG. See Electrocardiogram (ECG)
Echinacea, 490–491
Eclampsia, pregnancy-induced, 381
Economic analysis primer, 31–34, 33t
cost-benefit analysis, 34
cost effectiveness analysis, 33
cost minimization analysis, 32
cost utility analysis, 33
Economics, perioperative and critical care, 7–8
ECV. See Effective circulating volume (ECV)
Edema, causes of, 78t
Education, postsurgical, 423–425
Effective circulating volume (ECV), 72
Effective oncotic pressure, 162
Effective osmolality, 69
EGA. See Estimated gestational age (EGA)
Eicosapentaenoic acid (EPA), 498
E-journals, evidence-based, 16t
Elderly, surgery in, 217
Electrocardiogram (ECG), 147, 150–151, 168, 306
ASA classification system for, 150t
general recommendations for, 151t
Electrolyte(s), 146, 333–334, 518–519
Electrolyte homeostasis, 69–76

Electrosurgical bowel injury, 278
Embryo cryopreservation, 471
Emphysema, subcutaneous, 271–272
End tidal CO2 (EtCO2), 263
Endocarditis prophylaxis, 177
Endocervical curettage (ECC), 300
End-of-life decision making, 509
ascites, 522–523
bleeding, 528, 529t
constipation, 521–522
decision making, 527–528
electrolyte changes, 518–519
fatigue
evaluation of, 525–526
treatment of, 526
intestinal obstruction, 511–515
octreotide, 515
stent placement, 515–516
legal principles in, 527t
nausea and vomiting, 519–520
nutritional management, 516
parenteral nutrition, 518
pharmacologic support, 517–518
packed red blood cells
locoregional therapy, 529–530
systemic therapy, 530–532
pain control, 510–511
pharmacological management
benzodiazepines, 525
opioids, 524
unconventional therapies, 525
respiratory function, 523–524
Endometrial cancer, 329, 444, 478–479
adjuvant therapy
chemotherapy, 347–350
hormonal agents, 344
radiation, 344–347
familial genetic syndromes, 330–331
precursor lesions, 331–333
preoperative evaluation
cardiac evaluation, 334–335
chest x-ray, 335
deep venous thrombosis prophylaxis, 336–337
diagnostic imaging, 335
electrolytes, 333–334
hemoglobin, 333
renal function, 334
tumor markers, 335–336
postoperative hormone replacement, 343
Index

Endometrial cancer (Continued)
postoperative surveillance, 342–343
staging
endometrioid adenocarcinoma, 337–341
uterine papillary serous carcinoma, 341–342
treatment of
chemotherapy, 353–354
hormonal, 350–351
radiation, 351–353
surgery, role of, 350
Endometrial intraepithelial carcinoma (EIC), 332
Endometrioid adenocarcinoma, 337–341, 338
Endomyometritis, 383
Endoscopic transluminal stent placement, 515
ENOXACAN I, 185
ENOXACAN II, 186
Enteral feedings, 115
Enteral nutrition, 115–119
access to the alimentary tract, 117–118
comparison of, 136–138
complications of, 119
formulation of enteral feeding products, 115–117
potential complications during, 120
prescribing therapy, 118–119
site of nutrient delivery, 117
Enterocolostomy, 304
Enterostomal therapist, 426
Ephedra, 491–492
Epidural anesthesia, 285
Epidural opiates, 458–460
Epithelial ovarian carcinoma, 444
Epithelialization, 396
Erythromycin, 176
Estimated gestational age (EGA), 216
Evidence-based medicine (EBM), 3–7, 488–490
art of, 14
best practices loop model, 36
concept of, 12
databases for, 17
defined, 4
electronic databases for, 6
evolution of, 3
external data gathering, 15
GRADE system for, 18
grading published data, 18–20
guideline attributes for, 18, 34–36
implementation of, 7
information in, 3
internet web sites for, 13
meta-analysis of, 17–18
misperception of, 14
online journals of, 17
published data for, 18–20
quality improvement in, 5
radical changes in, 4
relevance interpretation tools in, 15
resurgence of interest in, 13
statistics issues in, 23–26
technological advances in, 7
textbooks for, 17
Extra-abdominal infection sites. See under Superficial and deep incisional SSI
Extracellular fluid (ECF), 69
hypotonicity, 71
tonicity, 71
Extracellular fluid compartment, 162
Extraperitoneal insufflation, 272
Factor V Leiden, mutations in, 51
Familial genetic syndromes, 330–331, 331
Fasting, preoperative, 307
Fat overload syndrome, 126
Fatigue, 525–526
Femoral vessel rupture, 401
Fertility preservation in cancer patient
cervical cancer, 475–478
chemotherapy, 470–471, 471–473
endometrial cancer, 478–479
ovarian cancer
germ cell tumors, 479–480
invasive epithelial tumors, 480–481
tumors of low malignant potential, 480
ovarian function preservation
embryo cryopreservation, 471
oocyte cryopreservation, 471–472
ovarian suppression, 472–473
ovarian tissue cryopreservation and transplantation, 472
radiation, 469–470
Fertility-preserving surgery, 318–319
Fetal death, 430–431, 431
Fever, postoperative, 235–236
FFP. See Fresh frozen plasma (FFP)
FHR. See Perioperative fetal heart rate (FHR)
125-fibrinogen uptake tests, 181
Fistula, 405–407
Flavonoid metabolism, 493
Fluid(s), 69–76
body compartment, 70f
composition of, 191f
electrolyte composition of the major compartment, 70f
management of
intraoperative, 96–97
postoperative, 97–98
preoperative, 95–96
resuscitation, 92–94
hypertonic saline, 93–94
tonicity, 71
Fluid and electrolyte therapy, 88–108
ascites, management of, 107–108
fluid resuscitation, 92–94
gastrointestinal losses, replacement of, 94–95
hypernatremia, analysis and management of, 104–106, 105f
hyponatremia, analysis and management of, 100–103, 102f
intraoperative fluid management, 96–97
maintenance therapy, 88–91
metabolic acidosis, management of, 106–107
metabolic alkalosis, management of, 107
oliguria, 98–100, 99f
postoperative fluid management, 97–98
postoperative renal failure, 100
preoperative fluid management, 95–96
status of fluid and electrolyte, 95
Fluoroquinolone, 172, 249
Foley catheter(s), 245
Foley catheter care, 195–196
Forced vital capacity (FVC), 210
FRC. See Functional residual capacity (FRC)
Fresh frozen plasma (FFP), 203
Functional assessment of cancer therapy (FACT), 526
Functional residual capacity (FRC), 166
Fungal infection, 252–253
Funicular pain, 450
FVC. See Forced vital capacity (FVC)
Garlic, 492–493
Gas embolism, 268–269
Gastrointestinal distention, 267
Gastrointestinal losses, replacement of, 94–95
volume and electrolyte content of, 94t
Gastrointestinal tract injury, 277–280, 279f
Gaussian distributions, 28
Genitourinary (GU) cancers, 217
Gentamicin, 209
Germ cell tumors, 479–480
GI bleeding prophylaxis, 187
GI injury, surgical complications in, 203–205
Gibbs-Donnan effect, 75
Ginkgo, 493–494
Ginseng, 494
Glipizide, 207
Glucocorticoids, 188
Glucose, 120, 122–123
vs. lipid as caloric source, 133
Glucose-dependent glycolytic tissues, 90
Glucose intolerance, 135
Glucosuria, 104
Glutamine, 499
Glyburide, 207
Glycogen, 108
Gore-Tex, 309
Groin wound breakdown, 401
Gynecologic Oncology Group (GOG) trial, 302, 343, 350, 352f, 391
in ovarian cancer, 365
Gonadotropin-releasing hormone (GnRH), 472, 473
Guilt, 422
GRADE system, for EBM, 18
Grave’s disease, 214
Grief work, stages of, 431t
GU. See Genitourinary (GU) cancers
Guideline attributes for, EBM, 34–36
Gynecologic oncology. See Pain in gynecologic oncology
Gynecologic surgery patients, counseling for, 438t
Hair removal, preoperative, 307
Halothane anesthesia, 271
Hand hygiene, surgical, 241–242
Harris–Benedict equation, 193
546  Index

H2 blockers. See Histamine type 2 (H2) blockers
Health Care Surrogate Acts, 429
Health Information Research Unit (HIRU), 17
Health years equivalent (HYE) metric, 32
Hematoma, 47
Hemoglobin, 333
Hemorrhage, 271, 401
Hemostasis, 267
Henderson- Hasselbach equation, 78
Heparin, 51, 56, 337
Hepatic blood flow, 267
Hepatic perfusion, 267
Herbal medication, perioperative, 487
beneficial perioperative substances
arginine, 497
chitosan, 498
complementary and alternative medicine, 488–490
detrimental perioperative substances
echinacea, 490–491
ephedra, 491–492
garlic, 492–493
ginkgo, 493–494
ginseng, 494
kava, 494–495
St. John’s Wort, 495–496
valerian, 496–497
eicosapentaenoic acid, 498

Hormonal agents, 344
Hormone replacement, postoperative, 343
Hyperbaric oxygen therapy, 48, 399, 400
Hypercalcemia, 518
Hyperemesis gravidarum, 383
Hyperglycemia, 128, 207
Hyperkalemia, 192
emergency treatment of, 101
Hyperlipidemia, 135
Hypernatremia, 163, 191
analysis and management of, 104–106, 105f
Hypoparathyroidism, 215–216
Hypokalemic alkalosis, 82
Hyponatremia, 190
analysis and management of, 100–103, 102f
Hypoparathyroidism, 215–216
Hypopituitarism, 215
Hypothermia, 165, 189, 273
perioperative, 241
Index

Hypothyroidism, 214–215
Hypotonic hyponatremia, 163
Hypovolemia, 96, 100
    - sign of fluid loss, 96t
Hypoventilation, 209
Hypoxemia risk factors, 265
Hysterectomy, 378
    - laparoscopic, 280, 281
ICF. See Intracellular fluid (ICF)
ICU. See Intensive care units (ICU)
Illness, catabolic responses to, 113f
Incomplete (initial) surgery
    - known metastatic, 369
    - presumed nonmetastatic, 368–369
Insulin therapy, 207
Intensive care unit (ICU), 178
    - delirium, 434–435
    - psychological complications in, 431–436
    - risk factors in, 433t
Intermittent pneumatic compression (IPC), 182
Internal jugular vein, 44–45
    - anatomy of, 44
    - insertion technique, 44–45
International Federation of Gynecologists
    and Obstetricians (FIGO), 301, 339f, 384
Interstitial fluid compartment, 162
Intestinal obstruction, 511–516
    - surgical complications in, 203–205, 204f
See also under End-of-life decision making
Intra-abdominal infections
    - abscesses, 248–249
    - bowel related, 248
    - gynecologic ascending, 247
    - lymphocyst infection, 249
    - treatment of
        - intravenous antibiotic choices, 249–250
        - oral antibiotics, 250
Intracellular fluid (ICF), 69
Intracellular volume compartment, 162
Intraoperative blood loss, 309
Intraoperative fluid management, 96–97
Intraperitoneal catheters, 62–63
Intraperitoneal therapy, 370
Intravenous antibiotics, 249–250
Intravenous chemotherapy, 369–370
Intravenous pyelogram (IVP), 314
Ischemia, myocardial, 270–271
    - complications of, 63
    - technique of, 63
IntraS, 200
Intravascular device related bloodstream infections, rates of, 50t
Intravascular volume expansion, 92
Intravenous pyelography (IVP), 168
Intrinsic renal disease, 211
Invasive epithelial tumors, 480–481
IPC. See Intermittent pneumatic compression (IPC)
Isotonic hyponatremia, 103
IVP. See Intravenous pyelography (IVP)
Jackson Pratt drain, 63
Japanese Gynecologic Oncology Group
    (JGOG), 348
Jejunal feedings, 117
Juxtaglomerular apparatus, 72
Juxtaglomerular cells, 164
J-wire in situ, 53
Kava, 494–495
Kava dermopathy, 495
Kavalactones, 494
Kayexalate enemas, 192
Krukenberg’s tumors, 364
Lactic acidosis, 106
Laparatomy, 174
Laparoscopic lymph node staging, 317
Laparoscopy, 174, 244, 373
    - anesthetic complications, 272–273
    - cardiovascular collapse
        - gas embolism, 268–269
        - metabolic abnormalities, 268
        - myocardial ischemia, 270–271
        - pneumomediastinum, 270
        - pneumopericardium, 270
        - pneumothorax, 269–270
    - complications, 268–285
    - deep venous thrombosis, 273–274, 274f
    - extraperitoneal insufflation, 272
    - gastrointestinal tract injury, 277–280, 279f
    - hemorrhage
        - cardiac arrhythmia, 271
        - hypothermia, 273
Index

Laparoscopy (Continued)
- incisional complications
  - incisional hernias, 283
  - wound dehiscence, 283
  - wound infections, 283
  - nerve injuries, 282–283
  - operative injuries, 274–275
  - pneumoperitoneum, physiology of, 261, 262
    - alternate gases, 263
    - carbon dioxide, 262–263
    - cardiovascular changes, 264–265
    - gastrointestinal distention, 267
    - lung volumes, 264
    - neuroendocrine hormonal response, 265–267, 266
    - oxygenation, 264, 265
    - renal perfusion, 267
    - splanchnic and hepatic perfusion, 267
    - ventilation, 264
  - postoperative nausea, 284–285
  - postoperative pain, 283–284
    - during pregnancy, 286
    - simulation training, 287–288
  - subcutaneous emphysema, 271–272
  - urinary tract injury
    - bladder injury, 280–281
    - urachal and vesicourachal diverticulum, 281
  - ureteral injuries, 282
  - vascular injury
    - minor, 275–276
    - major, 276–277
    - mesenteric, 277
  - bowel
d  - Laparotomy
    - exploratory, 249
    - for ovarian cancer, 367
  - Large loop excision of the transformation zone (LLETZ), 300
  - Laryngeal mask airway (LMA), 273
  - Laxatives, 521
  - LCL. See Lower control limit (LCL)
  - Learning organization, 14
  - Leuconostoc mesenteroides, 93
  - Likelihood ratio (LR), 28
  - Linoleic acid, 111
  - Lipid, 120, 123–124
    - soluble drugs, 458
  - Lipomul, 121
  - Lipoprotein–lipase enzymes, 121
  - Liver disease, 213
  - LMWH. See Low molecular weight heparin (LMWH)
  - Localized pain, 450
  - Locoregional therapy, 529–530
  - Long-term venous catheterization, 52–54
    - insertion technique, 53–54
    - overview, 52–53
  - Low malignant potential (LMP) tumors, 480
  - Low molecular weight heparin (LMWH), 182
  - Lower control limit (LCL), 12
  - LR. See Likelihood ratio (LR)
  - Lymph node dissection, drainage after, 309
  - Lymphedema, 403–404
    - and lymphocysts, 316–317
  - Lymphadenectomy, 340, 341
    - inguinal, 390, 391, 401
    - pelvic, 391
  - Lymphocyst, 195, 402–403
    - infection, 249
    - lymphedema and, 316–317
  - Lymphoscintigraphy, 391
  - Lymphovascular space invasion (LVSI), 300
  - Lynch syndrome, 330
  - Ma huang, 491
  - Maintenance fluid requirements, 91, 91
  - Maintenance therapy, 88–91
  - Major vascular injury, 276–277
  - Malignant bowel obstruction (MBO), 511–512, 512
    - 514
  - Malignant hyperthermia, 236
  - Malnutrition, 515
  - Marginal cost, 33
  - Markov model, 30
  - MCT. See Medium chain triglycerides (MCT)
  - Medical subject headings (MeSH), 15
  - Medium chain triglycerides (MCT), 116
  - MEDLINE, 6, 15
    - electronic searches in, 15
    - keyword searches in, 16
  - Medroxyprogesterone acetate, 478
  - Medscape, 15
  - Megestrol (Megace), 478
  - Mesenteric vascular injury, 277
MeSH. See Medical subject headings (MeSH)
Metabolic acidosis, 83
causes of, 88t
management of, 106–107
Metabolic alkalosis, 83
causes of, 89t
management of, 107
Methimazole, 214
Metronidazole, 176, 179
MI. See Myocardial infarction (MI)
Microinvasive adenocarcinoma, 301, 477
Microinvasive cervix cancer, 300–301
Microsatellite Instability (MSI), 331
Minor vascular injury, 275–276
Molar gestation
anemia, 380–381
cardiopulmonary insufficiency, 377–379
coungulopathy, 381
eclampsia, 381
endometriosis, 383
hyperemesis gravidarum, 383
hypothyroidism, 382–383
management guidelines for evidence-based, 384–385
therapeutic goals, 384
postevacuation delayed bleeding, 383–384
pregnancy-induced hypertension (PIH), 381–382
pulmonary edema, 379–380
trophoblastic embolization, 377–379
Micronutrients, 111
Mild vaginal cuff inflammation, 197
Miscarriage, 431
Monobactams, 249
Monoamine oxidase inhibitor (MAOI), 496
Morphine, 457
Morphine sulfate PCA dosing guidelines, 458t
Mortality, patient’s, 428–430
Multidimensional fatigue index (MFI), 526
Myocutaneous flaps, 408
Myocardial infarction (MI), 165
perioperative, risk for, 172t
postoperative, Goldman risk factors for, 171, 171t
Myoclonic spasms, 460
Na–K–ATPase pump, 70
Nasogastric decompression, 196
National Confidential Enquiry into Perioperative Deaths, 513
National Library of Medicine, 15
National Nosocomial Infections Surveillance System (NNIS), 237
National Surgical Infection Prevention Project, 173
Nausea
postoperative, 284–285
and vomiting, 194–195, 519–520
Necrotizing fasciitis, 247, 398–400
Necrotizing soft tissue infections, 398–400
Nephrogenic diabetes insipidus, 104
Nerve injuries, 282–283
Neuroendocrine hormonal response, 265–267, 266t
Neuropathic pain, 449–450
Neurotmesis, 282
Nitrous oxide, 263, 285
NNT. See Number needed to treat (NNT)
Nociceptive pain, 449
Non-carbonic acids, 77
Noncuffed hemodialysis catheters, 50
Noninvasive ventilation (NIV), 524
Nonmalignancy-related pain, 445, 447t
Nonopioid analgesics, 455–456
Nosocomial bacteremias, 171
Nosocomial pneumonia, 250
Number needed to treat (NNT), 24
outcome of, 26
Nutrient preparations
essential components of, 110–111
formulations of, 113–115
Nutrient requirements, estimation of, 111–113
Nutritional management, 516–528
Nutritional support
for postoperative management, 192–193
Obstructive uropathy, 211
Octreotide, 515, 530
Oliguria, 98–100, 99t
Omentectomy, 188
Oncotic pressure, effective, 162
Ondansetron, 195, 285
Online journals, for EBM, 17
Online structured reviews and guidelines, 16t
Index

Oocyte cryopreservation, 471–472
Operational tools, overview of, 8–9
Opioid(s), 524
Opioid analgesics (algorithm), 166, 466
Op-Site, 200
Oral antibiotics, 250
Oral contraceptives (OC), 472
Oral warfarin, 51
Ornithine ketoglutarate (OKG), 499
Orthotopic transplantations, 472
Osler’s apprentice, 3
Osmotically effective solute, 69
Osmoreceptors, 72
Osteomyelitis pubis, 400
Oxygenation, 264, 265
Oxytocin, 378
Ovarian carcinoma, pelvic masses and
diagnostic considerations, 364–368
diagnosis, certain
  adjuvant therapy, 369–374
  incomplete surgery, 368–369
diagnosis, uncertain, 361–364
  risk of malignancy index, 362
  ovarian cancer surgical staging procedure, 366
  pelvic masses
    at high risk, 364
    at low risk, 363
  reassessment laparotomy for, 367
Ovarian cancer. See under Fertility
  preservation in cancer patient
Ovarian suppression, 472–473
Ovarian tissue cryopreservation and
  transplantation, 472
Ovid, 16
Opiate analgesics, 456
  patient-controlled, 457–458, 457f

Packed red blood cells (PRBCs), 379
Locoregional therapy, 529–530
Systemic therapy, 530–532
Pain
  assessment behavior scale, 511
  intensity scales, 452f
  management, 194
  postoperative, 283–284
Pain in gynecologic oncology, 443, 444
  assessment, 447–448
  and cancer therapy, 451–452
  characteristics of
    acute, 448–449
    chronic, 449
    localized, 450
    neuropathic, 449–450
    nociceptive, 449
    referred, 450
  clinical assessment, 444–447
  management of
    adjuvant analgesic drugs, 460–461
    barriers to, 455
    epidural opiates, 458–460
    nonopiate analgesics, 455–456
    nonpharmacological measures, 461
    opiate analgesics, 456
    patient-controlled opiate analgesia, 457–458
    pharmacological, 453–460
    quality assessment, 461
    measurement of, 452–453
    tumor-related pain syndromes, 450–451
  types of, 445
    drug abuse/addiction, 445
    dying patient and, 447
    nonmalignancy-related pain, 445, 447
    in patients with psychiatric conditions, 446
    in pregnant patient, 445
    therapy-related, 445, 447
Pamidronate, 519
Pap smear test, 319
Para-aortic nodal involvement, risk of, 338
Paracentesis, 61–62
  complications for, 62
  procedure for, 62
Paradoxical aciduria, 82
Paralytic ileus, 167
  surgical complications in, 203–205
Parathyroid hormone (PTH), 215
Parathyroid hormone–related protein
  (PTHrP), 519
Parenteral nutrition, 518
Partial exenteration, 305
Partial thromboplastin time (PTT), 381
Pedicle flap, 409
Pelvic infections. See Intra-abdominal
  infections
Pelvic masses. See Ovarian carcinoma,
  pelvic masses and
<table>
<thead>
<tr>
<th>Index</th>
<th>551</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pelvic nodal involvement, risk of, 338t</td>
<td>Parenteral nutrition</td>
</tr>
<tr>
<td>Pelvic radiation, 345</td>
<td>comparative composition of, 133</td>
</tr>
<tr>
<td>Pentoxifylline, 407</td>
<td>comparison of, 136–138</td>
</tr>
<tr>
<td>Peritoneal closure, 244</td>
<td>adjunct to chemotherapy, 137</td>
</tr>
<tr>
<td>Peritonitis, 248</td>
<td>adjunct to radiation therapy, 137–138</td>
</tr>
<tr>
<td>Pharmacoeconomics, 253</td>
<td>adjunct to surgery, 137</td>
</tr>
<tr>
<td>Pneumomediastinum, 270</td>
<td>complications of, 125–130</td>
</tr>
<tr>
<td>Pneumonia, 250–251</td>
<td>drug toxicity, 125–126</td>
</tr>
<tr>
<td>Pneumopericardium, 270</td>
<td>metabolic complications, 127–130</td>
</tr>
<tr>
<td>Pneumoperitoneum, physiology of. See under Laparoscopy</td>
<td>systemic sepsis, 126–127</td>
</tr>
<tr>
<td>Pneumothorax, 269–270</td>
<td>vascular access, 126</td>
</tr>
<tr>
<td>Positron emission tomography (PET), 303</td>
<td>indications for, 132</td>
</tr>
<tr>
<td>Postevacuation delayed bleeding, 383–384</td>
<td>nonnutritional effects of, 130–132</td>
</tr>
<tr>
<td>Postoperative chemotherapy. See under Adjuvant therapy for ovarian cancer</td>
<td>on intestinal tract, 131</td>
</tr>
<tr>
<td>Postoperative nausea and vomiting (PONV), 285</td>
<td>on liver, 131</td>
</tr>
<tr>
<td>Postoperative radiation therapy in endometrial cancer (PORTEC) trial, 344, 346</td>
<td>on pancreas, 131</td>
</tr>
<tr>
<td>Postvoid residual (PVR) volumes, 309</td>
<td>on respiratory system, 131–132</td>
</tr>
<tr>
<td>Practical clinical trials (PCTs), 490</td>
<td>on stomach, 130–131</td>
</tr>
<tr>
<td>Practice advisory task force for preanesthesia evaluation, 335</td>
<td>Partial thromboplatin time (PTT), 146</td>
</tr>
<tr>
<td>PRBC. See Packed red blood cell (PRBC)</td>
<td>Patient expected even rate (PEER), 26</td>
</tr>
<tr>
<td>Preanesthetic tests, 365</td>
<td>Patient-controlled opiate analgesia, 457–458, 457t</td>
</tr>
<tr>
<td>Precursor lesions, 331–333</td>
<td>PE. See Pulmonary embolism (PE)</td>
</tr>
<tr>
<td>Pregnancy-induced hypertension (PIH), 380, 381–382</td>
<td>Peel-away catheter, 54</td>
</tr>
<tr>
<td>Preoperative serum electrolytes, 333</td>
<td>PEER. See Patient expected even rate (PEER)</td>
</tr>
<tr>
<td>Pressure dressings, 272</td>
<td>Pelvic cellulitis, 197</td>
</tr>
<tr>
<td>Prophylactic antibiotics, 307–308</td>
<td>Penicillins, 209</td>
</tr>
<tr>
<td>Prostanoids, 381</td>
<td>Penrose drain, 195</td>
</tr>
<tr>
<td>Pseudomonas, 252</td>
<td>Percutaneous nephrostomies, 195–196</td>
</tr>
<tr>
<td>PTEN, 331</td>
<td>Perioperative bleeding, 202–203</td>
</tr>
<tr>
<td>Pulmonary care (cervical cancer), 311</td>
<td>Perioperative cardiac assessment, 170–171, 170t</td>
</tr>
<tr>
<td>Pulmonary edema, 379–380</td>
<td>Perioperative care economics, 7–8</td>
</tr>
<tr>
<td>Pulmonary embolism, 317, 401</td>
<td>Perioperative fetal heart rate (FHR), 216</td>
</tr>
<tr>
<td>Pyelonephritis, 245, 250</td>
<td>Perioperative hypoalbuminemia, 162</td>
</tr>
<tr>
<td>Parenteral and enteral nutrition, 108–122</td>
<td>Perioperative infections</td>
</tr>
<tr>
<td>enteral nutrition, 115–119</td>
<td>clinical realities, 254</td>
</tr>
<tr>
<td>nutrient preparations</td>
<td>pharmacoeconomics, 253</td>
</tr>
<tr>
<td>essential components of, 110–111</td>
<td>postoperative fever, 235–236</td>
</tr>
<tr>
<td>formulation of, 113–115</td>
<td>risk factors for, 237</td>
</tr>
<tr>
<td>nutrient requirements, estimation of, 111–113</td>
<td>SSIs. See Surgical site infections</td>
</tr>
</tbody>
</table>
Index

Perioperative infections (Continued)
surgical infection genesis, 236–237
surgical procedure classification, 237–238

Perioperative prophylaxis
informed consent, 167–168, 168f
laboratory screening, 168–171, 169f
medical history of, 167–168
physical examination of, 167–168
surgical wound infection, prevention of, 171–176
Perioperative screening tests, 171
Perioperative thromboembolism
prophylaxis, 183–184t
Peripherally inserted central catheter (PICC), 50
Peritonitis, 63
Phenothiazines, 435
PICC. See Peripherally inserted central catheter (PICC)
Plasma, 162
expanders, 91t
oncotic pressure, 75
osmolality, 71, 164f
function of, 72f
Pleural catheter, 522
Pleural cavity procedures
chest tube thoracostomy, 58–60
pleurodesis, 60–61
thoracentesis, 56–58
Pleurodesis, 60–61
complications of, 61
indications for, 60
procedure for, 60–61
PleurX tunneled catheters, 61t
Pneumothorax, 47
PNI. See Prognostic nutritional index (PNI)
POI. See Postoperative ileus (POI)
Polyneuropathy, 451
Positional obstruction, with subclavian catheters, 51–52
P<sub>osm</sub>. See Plasma osmolality (P<sub>osm</sub>)
Postoperative albumin, 162
Postoperative fluid management, 97–98
Postoperative ileus (POI), 167
Postoperative management, general problems in, 189–200
decubital care, 198–200
fluid and electrolyte replacement, 189–192
nausea and vomiting, 194–195

nutritional support, 192–193
pain management in, 194
recovery room area, initial management in, 189
tubes and drains, 195–196
wound infections, 196–198
Postoperative recovery room area, initial management in, 189
Postoperative renal failure, fluid and electrolyte management of, 100
Pregnant patients, surgery in, 216–217
Preoperative evaluation
chest radiograph, 151–154
electrocardiogram, 150–151
laboratory tests, 147–150
overview, 145
pulmonary function testing, 154–157
routine testing, impact of, 145–147
Preemptive analgesia, 450
Premature ovarian failure (POF), 471
Preoperative fluid management, 95–96
Prerenal azotemia, 211
Progestins, 478
Prognostic nutritional index (PNI), 109
Prothrombin G20210A, mutations in, 51
Prothrombin time (PT), 146
Pseudohyponatremia, 103
Pseudomonas, 209
Psychosocial considerations, perioperative, 419
dehth and dying, issues of
fetal death, 430–431
patient’s mortality, 428–430
gynecologic surgery patients, counseling for, 438t
psychological complications in ICU, 431
anxiety, 435–436
delirium, 433–435
depression, 436
extrinsic factors, 432, 433t
ICU delirium, 434–435
intrinsic factors, 432, 433t
sexual/emotional problems
frequency of, 420–423
postsurgical education, 423–425
treatment, 425–427
PTH. See Parathyroid hormone (PTH)
PTT. See Partial thromboplastin time (PTT)
Published data for EBM, grading of, 18–20
PubMed, 16
Pulmonary artery catheterization, 54–56
insertion technique, 54–55
Pulmonary complications, 209–211
Pulmonary disease, 135
Pulmonary embolism (PE), 165
Pulmonary function testing, 154–157
QALY. See Quality adjusted life years (QALY)
Quality adjusted life year (QALY), 32, 149
Quality of Reporting of Meta-analyses (QUOROM), 13
QUOROM. See Quality of Reporting of Meta-analyses (QUOROM)
Radiation, 344–347, 351–353, 469–470
fibrosis, 451
necrosis and fistula, 405–407
ovarian function preservation during, 473–475
Radiation Therapy Oncology Group (RTOG), 302
Radical hysterectomy. See under Cervical carcinoma
Radical vaginal hysterectomy, 317–318
Radical vaginal trachelectomy (RVT), 477
Radionecrotic wounds, 405
Radiotherapy, 529
RAND Corporation, 5
Randomized controlled trials (RCT), 12, 490
evaluation of, 20–21
Ratios, 24
RBC. See Red blood cells (RBC)
RCT. See Randomized controlled clinical trial (RCT)
Receiver operating characteristics (ROC) curves, 27, 28f
Recovery room area, postoperative, 189
Rectal stenting, 516
Rectocele, 404
Red blood cells (RBC), 202
Reexpansion pneumonitis, 58
Refeeding syndrome, 129
Referred pain, 450
Renal disease, 211–212
Renal perfusion, 267
Renin, 164
Retrograde pyelography, 314
Risk of malignancy index (RMI), 362f
Robotic radical hysterectomy, 318
Renin–angiotensin–aldosterone system, 72, 73f
Respiratory acidosis, 83
causes of, 86t
Respiratory alkalosis, 83
causes of, 87t
Respiratory disturbances, causes of, 82
Respiratory function, 523–524
Ribose, 500
Ringer’s solution, 96, 106
ROC. See Receiver operating characteristics (ROC) curves
Routine adjunctive nutrition therapy, 137
Royal College of Radiologists, 152
Russell, Bertrand, 11
SAFE. See Saline vs. Albumin Fluid Evaluation (SAFE) trial
Saline vs. Albumin Fluid Evaluation (SAFE) trial, 92
Secondary neurogenic diabetes insipidus, 104
Seldinger technique, for catheter, 45
Senge, P, 14
Sentinel lymph node biopsy, 392–394
Sentinel node identification, 317
Sepsis, 126–127, 381
management of central venous line, 49f
systemic, 252
Sepsis syndrome, 178
Serotonin, 195
Sexual function after radical hysterectomy, 313–314
Sexual rehabilitation component, 425, 426
Shell zone receptors, 165
Shewhart, W, 12
Short-term central venous catheterization, 43–44
general preparation of patient, 44
overview, 43–44
technique of, 44
Shunt therapy, 523
Simulation training, 287–288
Skin graft, 407
Skin preparation, preoperative, 307
Skin-fascial flaps, 408
Smoking cessation, 239
Index

Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), 286
Sodium forces governing transcapillary distribution, 75f renal control of, 73
Somatic nociceptive pain, 449
Southwest Oncology Group (SWOG), 302
SPC. See Statistical process control (SPC)
Spironolactone, 108
Splanchnic and hepatic perfusion, 267
Splenectomized patients, 188
Splenectomy, 188
Squamous cell carcinoma, 476
SSI. See Surgical site infection (SSI)
St. John’s Wort, 495–496
Standard bicarbonate, 85
Starling forces, 74
Statistical control charts, 12
Statistical process control (SPC), 11
Stent placement, 515–516
Steroid prophylaxis, 187–188
Stillbirth, 431t
Stomal care, 200–201 complications of, 200t guidelines for, 201t
Stool incontinence, 405
Strengthening Reporting of Observational studies in Epidemiology (STROBE), 13
STROBE. See Strengthening the Reporting of Observational studies in Epidemiology
Stroke volume (SV), 164, 263
Subclavian vein insertion, 45–46 anatomy of, 45 complications of, 46 insertion technique, 46
Subcutaneous emphysema, 271–272
Sulbactam, 197
wound closure, 244–245
See also Superficial and deep incisional SSI
Surveillance, Epidemiology and End Results (SEER) database, 301
Systemic vascular resistance (SVR), 379
Systemic vascular resistance index (SVRI), 263
Surgical wound infection, prevention of, 171–179
abdominal hysterectomy, 173–174
antibiotic prophylaxis, 176–179
bowel preparation, 174–176
laparatomy, 174
laparoscopy, 174
vaginal hysterectomy, 173–174
Surviving Sepsis Campaign, 92
SV. See Stroke volume (SV)
Swan–Ganz catheter, 44, 54–56
complications of, 55–56
insertion technique, 54–55
Sympathetic nervous system, 74

Tachyarrhythmias, 271
TBW. See Total body water (TBW)
Tenckhoff-type catheter, 63
Terminal intestinal obstruction (TIO), 511
Tetracycline, 60
Textbooks, for EBM, 17
Therapy-related pain, 445, 447t
Thoracentesis, 56–58
complications of, 57–58
procedure for, 57
types of, 56
Three-in-one system, 124–125, 125t
Thrombosis, 55
related to catheter, 50–51
clinical signatures of, 51
Thromboembolic prophylaxis, 308
Thromboembolic/arterial occlusion, 401–402
Thyroid disease, 214–216
hyperthyroidism, 214
hypothyroidism, 214–215
Thyroid-stimulating hormone (TSH), 382
Thyroid storm, 214
Thyrotoxicosis, 379
TIPS. See Transjugular intrahepatic portasystemic shunt (TIPS)

Tissue trauma, 235
Tobramycin, 209
Tonicity, 69
calculated from, 71
Toradol, 194
Tornado diagram, 31
Total body water (TBW), 69
Total laparoscopic radical hysterectomy, 318
Total parenteral nutrition (TPN), 119–122, 518
comparing methods of, 133–134
ease and safety of administration, 134
fluid restriction, 134
hyperlipidemia, 135
hyperglycemia, 135
pulmonary disease, 135
Total pelvic exenteration (TPE), 303
TPN. See Total parenteral nutrition (TPN)
Trace element requirements, 114t
Tramadol, 456
Transdermal fentanyl, 459
Transdermal scopolamine, 285
Transjugular intrahepatic portasystemic shunt (TIPS), 107
Trendelenburg position, 264, 282
patient placed in, 45
Trocar insertion, 274, 275
Trophoblastic deportation, 378
Trophoblastic embolization, 377–379
Tubal and drains, 195–196
Foley catheter care, 195–196
nasogastric decompression, 196
open and closed suction, 195
percutaneous nephrostomies, 195–196
Tubular acid secretion, rate of, 80
Tumor-induced hypercalcemia (TIH), 519
Tumor markers, 335–336
Tumor-related pain, 445
syndromes, 446t, 450–451

U.S. Preventive Services Task Force (USPSTF), 18
UCL. See Upper control limit (UCL)
UFH. See Unfractionated heparin (UFH)
Index

Ultrasonic coagulating shears, 278
Unfractionated heparin (UFH), 182
Univariate predictors, 350, 351
University of Wisconsin Medical School, 49
Upper control limit (UCL), 12
Urachal and vesicourachal diverticulum, 281
Ureteral injuries, 282
in pelvic surgery, 315
Urinalysis, 150
Urinary or stool incontinence, 405
Urinary tract infection, 251–252
Urinary tract injury. See under Laparoscopy
USPSTF. See U.S. Preventive Services Task Force (USPSTF)
Uterine papillary serous carcinoma (UPSC), 332, 341–342, 349–350, 349
Uterine prolapse, 404
Vaginal bleeding, 319
Vaginal hysterectomy, 173–174
Vaginal plethysmography, 422
Vaginosis, bacterial, 236, 242
Valerian, 496–497
Valeriana officinalis, 496
Vancomycin, 251, 252
Vancomycin prophylaxis, 172, 179
Vancomycin–resistant enterococcus faecium (VRE), 452
Vascular access
complications of, 126
procedures for
insertion complications, 46–52
internal jugular vein, 44–45
long-term venous catheterization, 52–54
overview, 43
pulmonary artery catheterization, 54–56
short-term central venous catheterization, 43–44
subclavian vein insertion, 45–46
Vascular endothelial growth factor (VEGF), 108, 523
Vascular injury. See under Laparoscopy
Vasopressin, 530
VEGF. See Vascular endothelial growth factor (VEGF)
Venous thromboembolism (VTE), 179–187, 273–274, 274, 308
in cancer patients, 182
National Comprehensive Cancer Network recommendations for, 185
risk factors for, 179
Ventilation, 264
Ventilation-perfusion (V-Q) scan, 29
Venting gastrotomy, 516
Verres needle, 272, 274, 276, 281
Verres puncture, 278
Vesicourachal diverticulum, 281
Vesicovaginal fistulas, 314
Video trainers, 287
Vesciourachal diverticulum, 281
Urinary or stool incontinence, 405
Urinary tract injury. See under Laparoscopy
USPSTF. See U.S. Preventive Services Task Force (USPSTF)
Uterine papillary serous carcinoma (UPSC), 332, 341–342, 349–350, 349
Uterine prolapse, 404
Vaginal bleeding, 319
Vaginal hysterectomy, 173–174
Vaginal plethysmography, 422
Vaginosis, bacterial, 236, 242
Valerian, 496–497
Valeriana officinalis, 496
Vancomycin, 251, 252
Vancomycin prophylaxis, 172, 179
Vancomycin–resistant enterococcus faecium (VRE), 452
Vascular access
complications of, 126
procedures for
insertion complications, 46–52
internal jugular vein, 44–45
long-term venous catheterization, 52–54
overview, 43
pulmonary artery catheterization, 54–56
short-term central venous catheterization, 43–44
subclavian vein insertion, 45–46
Vascular endothelial growth factor (VEGF), 108, 523
Vascular injury. See under Laparoscopy
Vasopressin, 530
VEGF. See Vascular endothelial growth factor (VEGF)
Venous thromboembolism (VTE), 179–187, 273–274, 274, 308
in cancer patients, 182
National Comprehensive Cancer Network recommendations for, 185
risk factors for, 179
Ventilation, 264
Ventilation-perfusion (V-Q) scan, 29
Venting gastrotomy, 516
Verres needle, 272, 274, 276, 281
Verres puncture, 278
Vesicourachal diverticulum, 281
Vesicovaginal fistulas, 314
Video trainers, 287
Vesciourachal diverticulum, 281
Urinary or stool incontinence, 405
Urinary tract injury. See under Laparoscopy
USPSTF. See U.S. Preventive Services Task Force (USPSTF)
Uterine papillary serous carcinoma (UPSC), 332, 341–342, 349–350, 349
Uterine prolapse, 404
Vaginal bleeding, 319
Vaginal hysterectomy, 173–174
Vaginal plethysmography, 422
Vaginosis, bacterial, 236, 242
Valerian, 496–497
Valeriana officinalis, 496
Vancomycin, 251, 252
Vancomycin prophylaxis, 172, 179
Vancomycin–resistant enterococcus faecium (VRE), 452
Vascular access
complications of, 126
procedures for
insertion complications, 46–52
internal jugular vein, 44–45
long-term venous catheterization, 52–54
overview, 43
pulmonary artery catheterization, 54–56
short-term central venous catheterization, 43–44
subclavian vein insertion, 45–46
Vascular endothelial growth factor (VEGF), 108, 523
Vascular injury. See under Laparoscopy
Vasopressin, 530
VEGF. See Vascular endothelial growth factor (VEGF)
Venous thromboembolism (VTE), 179–187, 273–274, 274, 308
in cancer patients, 182
National Comprehensive Cancer Network recommendations for, 185
risk factors for, 179
Ventilation, 264
Ventilation-perfusion (V-Q) scan, 29
Venting gastrotomy, 516
Verres needle, 272, 274, 276, 281
Verres puncture, 278
Vesicourachal diverticulum, 281
Vesicovaginal fistulas, 314
Video trainers, 287
Vesciourachal diverticulum, 281
Urinary or stool incontinence, 405
Urinary tract injury. See under Laparoscopy
USPSTF. See U.S. Preventive Services Task Force (USPSTF)
Uterine papillary serous carcinoma (UPSC), 332, 341–342, 349–350, 349
Uterine prolapse, 404
Vaginal bleeding, 319
Vaginal hysterectomy, 173–174
Vaginal plethysmography, 422
Vaginosis, bacterial, 236, 242
Valerian, 496–497
Valeriana officinalis, 496
Vancomycin, 251, 252
Vancomycin prophylaxis, 172, 179
Vancomycin–resistant enterococcus faecium (VRE), 452
Vascular access
complications of, 126
procedures for
insertion complications, 46–52
internal jugular vein, 44–45
long-term venous catheterization, 52–54
overview, 43
pulmonary artery catheterization, 54–56
short-term central venous catheterization, 43–44
subclavian vein insertion, 45–46
Vascular endothelial growth factor (VEGF), 108, 523
Vascular injury. See under Laparoscopy
Vasopressin, 530
VEGF. See Vascular endothelial growth factor (VEGF)
Venous thromboembolism (VTE), 179–187, 273–274, 274, 308
in cancer patients, 182
National Comprehensive Cancer Network recommendations for, 185
risk factors for, 179
Ventilation, 264
Ventilation-perfusion (V-Q) scan, 29
Venting gastrotomy, 516
Verres needle, 272, 274, 276, 281
Verres puncture, 278
Vesicourachal diverticulum, 281
Vesicovaginal fistulas, 314
Video trainers, 287
Vesciourachal diverticulum, 281
Urinary or stool incontinence, 405
Way’s classic technique, 391
Wolff–Parkinson–White syndrome, 147
Wound
  breakdown, 394–395
  care (cervical cancer), 311–312
  classification scheme, 236–237
  closure, 244–245
  dehiscence, 283
  healing, 396–398

infection, 196–198, 246–247, 283
management of, 197
prevention of, 198
purpose of, 196

Xa inhibitor, 182

Zero defects, 11
Zoledronate, 519